Biogen Idec (BIIB) has agreed to acquire full ownership of multiple-sclerosis drug Tysabri from...
Wednesday, February 6, 3:16 AM ETBiogen Idec (BIIB) has agreed to acquire full ownership of multiple-sclerosis drug Tysabri from Elan (ELN) for $3.25B plus future royalty payments. Biogen has co-marketed the injectable treatment, which generated revenue of $1.6B last year, with Elan for twelve years, with both firms splitting the profit until now. The deal comes as Biogen awaits approval for its BG-12 pill to treat MS. (PR)
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles